ATP-citrate lyase

Choose Selective ATP-citrate lyase Inhibitors

ATP-citrate lyase Products

  • All (4)
  • ATP-citrate lyase Inhibitors (4)
  • New ATP-citrate lyase Products
Catalog No. Product Name Information Product Use Citations Product Validations
S0277 BMS303141 BMS-303141 is a potent, cell-permeable inhibitor of ATP-citrate lyase (ACL) with IC50 of 0.13 μM. BMS-303141 shows inhibition of total lipid syntheses with IC50 of 8 μM in HepG2 cells.
EMBO J, 2022, e109463
Cancers (Basel), 2019,
S4864 2-Furoic acid 2-Furoic acid (2-Furancarboxylic acid, Pyromucic acid, 2-Carboxyfuran, α-furancarboxylic acid, α-furoic acid) is an organic compound most widely found in food products as a preservative and a flavoring agent.
S7953 ETC-1002 ETC-1002 (Bempedoic acid, ESP-55016),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
Biomed Pharmacother, 2021, 144:112325
J Cell Mol Med, 2020, 25
S8878 NDI-091143 NDI-091143 is a potent inhibitor of human ATP-citrate lyase(ACLY) with a Ki of 7.0 nM and an IC50 of 2.1 nM in the ADP-Glo assay.
Sci Rep, 2021, 11(1):22085
S0277 BMS303141 BMS-303141 is a potent, cell-permeable inhibitor of ATP-citrate lyase (ACL) with IC50 of 0.13 μM. BMS-303141 shows inhibition of total lipid syntheses with IC50 of 8 μM in HepG2 cells.
EMBO J, 2022, e109463
Cancers (Basel), 2019,
S4864 2-Furoic acid 2-Furoic acid (2-Furancarboxylic acid, Pyromucic acid, 2-Carboxyfuran, α-furancarboxylic acid, α-furoic acid) is an organic compound most widely found in food products as a preservative and a flavoring agent.
S7953 ETC-1002 ETC-1002 (Bempedoic acid, ESP-55016),also known as Bempedoic acid, is an orally available, once-daily LDL-C lowering small molecule designed to lower elevated levels of LDL-C and to avoid side effects associated with existing LDL-C lowering therapies.ETC-1002 is an activator of hepatic AMP-activated protein kinase (AMPK). It has potent inhibitory activity against hepatic ATP-citrate lyase(IC50=29 uM).
Biomed Pharmacother, 2021, 144:112325
J Cell Mol Med, 2020, 25
S8878 NDI-091143 NDI-091143 is a potent inhibitor of human ATP-citrate lyase(ACLY) with a Ki of 7.0 nM and an IC50 of 2.1 nM in the ADP-Glo assay.
Sci Rep, 2021, 11(1):22085
Tags: ATP-citrate lyase inhibitor